Brain 1H-MR spectroscopy in clinical neuroimaging at 3T

Journal of Neuroradiology

Volumn 36, Issue 1, 2009, Pages 24-40

  Jissendi Tchofo, P ^a   Baleriaux D ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

3T magnet; Brain tumors; Epilepsy; Proton spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; CORTICOSTEROID; GLUTAMIC ACID; GLUTAMINE; LITHIUM;

ARTIFACT; ARTIFACT REDUCTION; BIPOLAR DISORDER; BODY MOVEMENT; BRAIN; BRAIN DAMAGE; BRAIN DISEASE; BRAIN EDEMA; BRAIN HYPOXIA; BRAIN LEVEL; BRAIN LYMPHOMA; BRAIN TUMOR; CLINICAL PRACTICE; COMPUTER PROGRAM; DATA ANALYSIS; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EPILEPSY; GEOMETRY; HUMAN; MAGNETIC FIELD; MENTAL DISEASE; METABOLIC DISORDER; METABOLITE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREMATURITY; PROTEIN DETERMINATION; REVIEW; SAMPLING; SPECTROSCOPY; TRAUMATIC BRAIN INJURY; WHITE MATTER;

BRAIN DISEASES; BRAIN MAPPING; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 61849113737     PISSN: 01509861     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurad.2008.04.001     Document Type: Review

References (136)

1. Hetherington H.P., et al. Biological and clinical MRS at ultra-high field. NMR Biomed 10 (1997) 360-371
2. Di Costanzo A., et al. Proton MR spectroscopy of the brain at 3T: an update. Eur Radiol 17 (2007) 1651-1662
3. Nakada T. Clinical application of high and ultra high-field MRI. Brain Dev 29 (2007) 325-335
4. Barker P.B., Hearshen D.O., and Boska M.D. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 45 (2001) 765-769
5. Gonen O., et al. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal/noise ratio and resolution comparison. AJNR Am J Neuroradiol 22 (October 2001) 1727-1731
6. Juchem C., et al. Combined passive and active shimming for in vivo MR spectroscopy at high magnetic fields. J Magn Reson 183 (2006) 278-289
7. Koch K.M., et al. Dynamic shim updating on the human brain. J Magn Reson 180 (2006) 286-296
8. Hetherington H.P., et al. Robust fully automated shimming of the human brain for high-field 1H spectroscopic imaging. Magn Reson Med 56 (2006) 26-33
9. Koch K.M., et al. Dynamically shimmed multivoxel 1H magnetic resonance spectroscopy and multislice magnetic resonance spectroscopic imaging of the human brain. Magn Reson Med 57 (2007) 587-591
10. Traber F., et al. Shortening of the measurement time by 1H-MR turbo spectroscopic imaging of the brain. Rofo 166 3 (1997 Mar) 221-229
11. Dydak U., Meier D., Lamerichs R., and Boesiger P. Trading spectral separation at 3T for acquisition speed in multi spin-echo spectroscopic imaging. AJNR Am J Neuroradiol 27 (Aug 2006) 1441-1446
12. Dreher W., and Leibfritz D. Fast proton spectroscopic imaging with high signal/noise ratio: spectroscopic RARE. Magn Reson Med 47 (2002) 523-528
13. Tsai S.Y., et al. Fast mapping of the T2 relaxation time of cerebral metabolites using proton echo-planar spectroscopic imaging (PEPSI). Magn Reson Med 57 (2007) 859-865
14. Lin F.-H., et al. Sensitivity-encoded (SENSE) proton echo-planar spectroscopic imaging (PEPSI) in the human brain. Magn Reson Med 57 (2007) 249-257
15. Kima D.-H., Henrya R., and Spielman D.M. Fast multivoxel two-dimensional spectroscopic imaging at 3T. Magn Reson Imaging 25 8 (2007) 1155-1161
16. Schuster C., et al. Fast 3D 1H spectroscopic imaging at 3Tesla using spectroscopic missing-pulse SSFP with 3D spatial preselection. Magn Reson Med 57 (2007) 82-89
17. Star-Lack J., et al. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 38 2 (1997 Aug) 311-321
18. Kelley D.A.C., Wald L.L., and Star-Lack J.M. Lactate detection at 3T: Compensating J coupling effects with BASING. J Magn Reson Imaging 9 (1999) 732-737
19. Sacolick L.I., Rothman D.L., and Graaf de R.A. Adiabatic refocusing pulses for volume selection in magnetic resonance spectroscopic imaging. Magn Reson Med 57 (2007) 548-553
20. Lange T., et al. Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 27 (2006) 895-901
21. Keevil S.F. Spatial localization in nuclear magnetic resonance spectroscopy. Phys Med Biol 51 (2006) 579-636
22. Hu J., et al. Simultaneous detection of resolved glutamate, glutamine, and γ-aminobutyric acid at 4 T. J Magn Reson 185 (2007) 204-213
23. Pattany P.M., Massand M.G., Bowen B.C., and Quencer R.M. Quantitative analysis of the effects of physiologic brain motion on point-resolved spectroscopy. AJNR Am J Neuroradiol 27 (May 2006) 1070-1073
24. 1H NMR spectroscopy using an EEC localization test object. Phys Med Biol 40 7 (Jul 1995) 1293-1303
25. Xu D., et al. Spectroscopic imaging of the brain with phased-array coils at 3.0 T. Magn Reson Imaging 24 (2006) 69-74
26. Goelman G., Liu S., Hess D., and Gonen O. Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med 56 (2006) 34-40
27. Vion-dury J., Salvan A.M., Confort-gouny S., and Cozzone P.J. Atlas of brain proton magnetic resonance spectra part I: general and methodological considerations. J Neuroradiol 25 (1998) 207-212
28. Hurd R., et al. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med 51 (2004) 435-440
29. Sijens P.E., et al. 1H chemical shift imaging of the brain in guanidine methyltransferase deficiency, a creatine deficiency syndrome; guanidinoacetate accumulation in the gray matter. Eur Radiol 15 (2005) 1923-1926
30. Otaduy M.C.G., et al. Proton MR spectroscopy and imaging of a galactosemic patient before and after dietary treatment. AJNR Am J Neuroradiol 27 (Jan 2006) 204-207
31. Demir M.K., Iplikcioglu A.C., Dincer A., Arslan M., and Sav A. Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol 60 (2006) 48-55
32. Inglese M., Spindler M., Babb J.S., Sunenshine P., Law M., and Gonen O. Field, coil, and echo-time influence on sensitivity and reproducibility of brain proton MR spectroscopy. AJNR Am J Neuroradiol 27 (Mar 2006) 684-688
33. Hattingen E., et al. Evaluation of optimal echo time for 1HSpectroscopic imaging of brain tumors at 3Tesla. J Magn Reson Imaging 26 (2007) 427-431
34. Schult R.F., Lange T., Beck J., Meier D., and Boesiger P. Improved two-dimensional J-resolved spectroscopy. NMR Biomed 19 (2006) 264-270
35. Calvar J.A. Accurate 1H tumor spectra quantification from acquisitions without water suppression. Magn Reson Imaging 24 (2006) 1271-1279
36. Bartha R., Drost D.J., Menon R.S., and Williamson P.C. Spectroscopic lineshape correction by QUECC: Combined QUALITY deconvolution and Eddy Current Correction. Magn Reson Med 44 (2000) 641-645
37. Vion Dury J. Recommandations pour le contrôle de qualité en spectrométrie de résonance magnétique cérébrale. J Neuroradiol 26 (1999) 59-60
38. Hunjan S., et al. Quality assurance of magnetic resonance spectroscopic imaging-derived metabolic data. Int J Radiation Oncology Biol Phys 57 4 (2003) 1159-1173
39. van der Graaf M., et al. MRS quality assessment in a multicentre study on MRS-based classification of brain tumours. NMR Biomed (2007 Apr 26) [Epub ahead of print]
40. Julià-Sapé M., et al. A multi-centre, web-accessible and quality control-checked database of in vivo MR spectra of brain tumour patients. Magn Reson Mater Phys 19 (2006) 22-33
41. 1H MR spectroscopy of the brain: Absolute quantification of metabolites. Radiology 240 2 (August 2006) 318-332
42. Safriel Y., et al. Reference values for long echo time MR spectroscopy in healthy adults. AJNR Am J Neuroradiol 26 (June/July 2005) 1439-1445
43. 1H-MRS brain metabolite measurements at 3T. Magn Reson Imaging 24 (2006) 187-194
44. Vigneron D.B. Magnetic resonance spectroscopic imaging of human brain development. Neuroimaging Clin N Am 16 1 (2006 Feb) 75-85
45. Tate A.R., et al. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 19 (2006) 411-434
46. Fawke J. Neurological outcomes following preterm birth. Semin Fetal Neonatal Med 12 5 (2007) 374-382
47. Rutherford M., Malamateniou C., Zeka J., and Counsell S. MR imaging of the neonatal brain at 3Tesla. Eur J Paediatr Neurol 8 (2004) 281-289
48. De Vita E., et al. Magnetic resonance imaging of neonatal encephalopathy at 4.7 Tesla: initial experiences. Pediatrics 118 6 (December 2006) 1812-1821
49. Barkovich A.J. MR imaging of the neonatal brain. Neuroimaging Clin N Am 16 (2006) 117-135
50. Vigneron D.B., et al. Three-dimensional proton MR spectroscopic imaging of premature and term neonates. AJNR Am J Neuroradiol 22 (August 2001) 1424-1433
51. Kim D.H., Barkovich A.J., and Vigneron D.B. Short echo time MR spectroscopic imaging for neonatal pediatric imaging. AJNR Am J Neuroradiol 27 (Jun-Jul 2006) 1370-1372
52. Barkovich A.J., et al. Proton spectroscopy and diffusion imaging on the first day of life after perinatal asphyxia: preliminary report. AJNR Am J Neuroradiol 22 (October 2001) 1786-1794
53. Barkovich, et al. MR imaging, MR spectroscopy, and diffusion tensor imaging of sequential studies in neonates with encephalopathy. AJNR Am J Neuroradiol 27 (Mar 2006) 533-547
54. Roelants-Van Rijn A.M., et al. Value of 1H-MRS using different echo times in neonates with cerebral hypoxia-ischemia. Pediatr Res 49 (2001) 356-362
55. Cheong J.L.Y., et al. Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and absolute concentrations. AJNR Am J Neuroradiol 27 (Aug 2006) 1546-1554
56. Boichot C., et al. Term neonate prognoses after perinatal asphyxia: contributions of MR imaging, MR spectroscopy, relaxation times, and apparent diffusion coefficients. Radiology 239 3 (June 2006) 839-848
57. Barkovich A.J. An approach to MRI of metabolic disorders in children. J Neurorad 34 (2007) 75-88
58. Cecil K.M. MR spectroscopy of metabolic disorders. Neuroimaging Clin N Am 16 (2006) 87-116
59. Cecil K.M., and Kos R.S. Magnetic resonance spectroscopy and metabolic imaging in white matter diseases and pediatric disorders. Top Magn Reson Imaging 17 (2006) 275-293
60. Leuzzi V., et al. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J Inherit Metab Dis 30 (2007) 209-216
61. Hertz L., and Dienel G.A. Lactate transport and transporters: general principles and functional roles in brain cells. J Neurosci Res 79 (2004) 11-18
62. Roger J., Genton P., and Bureau M. La classification internationale des épilepsies et des syndromes épileptiques adoptée au Congrés de New Delhi (octobre 1989) : commentaires et traduction. Epilepsies 2 (1990) 183-197
63. Kuzniecky R.I. Neuroimaging of epilepsy: Therapeutic implications. J Am Soc Exp Neurotherapeutics 2 2 (2005) 384-393
64. Rinaldi G., et al. The international classification of the epilepsies and epileptic syndromes: An algorithm for its use in clinical practice. Epilepsy Res 41 (2000) 223-234
65. Knake S., Triantafyllou C., Wald L.L., Wiggins G., Kirk G.P., Larsson P.G., et al. 3T phased array MRI improves the presurgical evaluation in focal epilepsies: a prospective study. Neurology 65 7 (2005) 1026-1031
66. Guye M., Ranjeva J.P., Le Fur Y., Bartolomei F., Confort-Gouny S., Regis J., et al. 1H-MRS imaging in intractable epilepsies characterized by depth electrode recording. Neuroimage 26 (2005) 1174-1183
67. Krsek P., Hajek M., Dezortova M., Jiru F., Skoch A., et al. 1H MR spectroscopic imaging in patients with MRI-negative extratemporal epilepsy: correlation with ictal onset zone and histopathology. Eur Radiol 17 (2007) 2126-2135
68. Mueller S.G., Laxer K.D., Suhy J., Lopez R.C., Flenniken D.L., et al. Spectroscopic metabolic abnormalities in mTLE with and without MRI evidence for mesial temporal sclerosis using hippocampal short-TE MRSI. Epilepsia 44 7 (2003) 977-980
69. Imbesi S.G. Proton magnetic resonance spectroscopy of mesial temporal sclerosis analysis of voxel shape and position to improve diagnostic accuracy. J Comput Assist Tomogr 30 (2006) 287-294
70. 1H magnetic resonance spectroscopy at 3T in cryptogenic and mesial temporal lobe epilepsy. NMR Biomed 19 (2006) 544-553
71. Ranjeva, et al. Magnetic resonance spectroscopy of brain in epilepsy. Childs Nerv Syst 16 4 (2000) 235-241
72. Leite C.C., Lucato L.T., Sato J.R., Valente K.D., and Otaduy M.C.G. Multivoxel proton MR spectroscopy in malformations of cortical development. AJNR Am J Neuroradiol 28 (2007) 1071-1075
73. Ende G., Laxer K., and Knowlton R. Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology 202 (1997) 809-817
74. Carpentier A., Galanaud D., Puybasset L., Muller J.-C., Lescot T., et al. Early morphologic and spectroscopic magnetic resonance in severe traumatic brain injuries can detect "invisible brain stem damage" and predict "vegetative states". J Neurotrauma 23 5 (2006) 674-685
75. Marino S., Zei E., Battaglini M., Vittori C., Buscalferri A., et al. Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome. J Neurol Neurosurg Psychiatry 78 (2007) 501-507
76. Cohen B.A., Inglese M., Rusinek H., Babb J.S., Grossman R.I., and Gonen O. Proton MR spectroscopy and MRI-volumetry in mild traumatic brain injury. AJNR Am J Neuroradiol 28 (2007) 907-913
77. Wattjes M.P., Lutterbey G.G., Harzheim M., Gieseke J., Träber F., et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5T with 3.0 T. Eur Radiol 16 9 (2006) 2067-2073
78. Wattjes M.P., Harzheim M., Kuhl C.K., Gieseke J., Schmidt S., et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis?. AJNR Am J Neuroradiol 27 (2006) 1794-1798
79. Allen I.V., and McKeown S.R. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41 (1979) 81-91
80. Tiberio M., Chard D.T., Altmann D.R., Davies G., and Griffin C.M. Metabolite changes in early relapsing-remitting multiple sclerosis A two year follow-up study. J Neurol 253 (2006) 224-230
81. Inglese M., Li B.S.Y., Rusinek H., Babb J.S., Grossman R.I., and Gonen O. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50 (2003) 190-195
82. Fernando K.T.M., McLean M.A., Chard D.T., MacManus D.G., and Dalton C.M. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 127 (2004) 1361-1369
83. Wattjes M.P., Harzheim M., Lutterbey G.G., Klotz L., Schild H.H., and Träber F. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28 (2007) 1517-1522
84. Sastre-Garriga J., Ingle G.T., Chard D.T., Ramió-Torrentà L., McLean M.A., et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 62 (2005) 569-573
85. Castillo M., Kwock L., Scatliff J., and Mukherji S.K. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 6 1 (1998) 1-20
86. Möller-Hartmann W., Herminghaus S., Krings T., Marquardt G., Lanfermann H., Pilatus U., et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44 5 (2002) 371-381
87. Galanaud D., Nicoli F., Figarella-Branger D., Roche P., Confort-Gouny S., Le Fur Y., et al. MR spectroscopy of brain tumors. J Radiol 87 (2006) 822-832
88. Hollingworth W., Medina L.S., Lenkinski R.E., Shibata D.K., Bernal B., Zurakowski D., et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 27 7 (2006) 1404-1411
89. Omuro A.M., Leite C.C., Mokhtari K., and Delattre J.Y. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 5 11 (2006) 937-948
90. Croteau D., Scarpace L., Hearshen D., et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated gliomas. Neurosurgery 49 (2001) 823-829
91. Dowling C., Bollen A.W., Noworolski S.M., McDermott M.W., Barbaro N.M., Day M.R., et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 22 4 (2001) 604-612
92. McKnight T.R., von dem Bussche M.H., Vigneron D.B., Lu Y., Berger M.S., McDermott M.W., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 97 (2002) 794-802
93. Vigneron D., Bollen A., McDermott M., Wald L., Day M., et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging 19 (2001) 89-101
94. Law M., Yang S., Wang H., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24 (2003) 1989-1998
95. Law M., Cha S., Knopp E.A., Johnson G., Arnett J., and Litt A.W. High-grade gliomas and solitary metastases: Differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 222 (2002) 715-721
96. Pirzkall A., McKnight T.R., Graves E.E., Carol M.P., Sneed P.K., Wara W.W., et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 50 4 (2001) 915-928
97. Nelson S.J., Graves E., Pirzkall A., Li X., Antiniw Chan A., et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 16 4 (2002) 464-476
98. Pirzkall A., Li X., Oh J., Chang S., Berger M.S., et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59 1 (2004) 126-137
99. Chuang C.F., Chan A.A., Larson D., Verhey L.J., McDermott M., et al. Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas. Technol Cancer Res Treat 6 5 (2007) 375-382
100. Nelson S.J. Imaging of brain tumors after therapy. Neuroimaging Clin N Am 9 (1999) 801-819
101. Balmaceda C., Critchell D., Mao X., Cheung K., Pannullo S., DeLaPaz R.L., et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 76 (2006) 185-191
102. Dyke J.P., Sanelli P.C., Voss H.U., Serventi J.V., Stieg P.E., et al. Monitoring the effects of BCNU chemotherapy wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J Neurooncol 82 1 (2007) 103-110
103. Chan A.A., Lau A., Pirzkall A., Chang S.M., Verhey L.J., et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. J Neurosurg 101 3 (2004) 467-475
104. Nimsky C., Ganslandt O., von Keller B., and Fahlbusch R. Intraoperative high-field MRI: anatomical and functional imaging. Acta Neurochir Suppl 98 (2006) 87-95
105. Stadlbauer A., Nimsky C., Buslei R., Pinker K., Gruber S., et al. Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: Correlation of metabolic and histological changes at low tumor infiltration-initial results. Invest Radiol 42 4 (2007) 218-223
106. Ricci R., Bacci A., Tugnoli V., Battaglia S., Maffei M., et al. Metabolic findings on 3T 1H-MR spectroscopy in peritumoral brain edema. AJNR Am J Neuroradiol 28 7 (2007) 1287-1291
107. Galanaud D., Nicoli F., Chinot O., Confort-Gouny S., Figarella-Branger D., et al. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn Reson Med 55 6 (2006) 1236-1245
108. Schneider J.F., Viola A., Confort-Gouny S., Ayunts K., Le Fur Y., et al. Infratentorial pediatric brain tumors: the value of new imaging modalities. J Neuroradiol 34 1 (2007) 49-58
109. Luts J., Heerschap A., Suykens J.A., and Van Huffel S. A combined MRI and MRSI based multiclass system for brain tumour recognition using LS-SVMs with class probabilities and feature selection. Artif Intell Med 40 2 (2007) 87-102
110. Di Costanzo A., Scarabino T., Trojsi F., Giannatempo G.M., Popolizio T., et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 48 9 (2006) 622-631
111. Hattingen E., Pilatus U., Franz K., Zanella F.E., and Lanfermann H. Evaluation of optimal echo time for 1H-spectroscopic imaging of brain tumors at 3Tesla. J Magn Reson Imaging 26 2 (2007) 427-431
112. Hazany S., Hesselink J.R., Healy J.F., and Imbesi S.G. Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology 49 2 (2007) 121-127
113. Harris L.M., Davies N., Macpherson L., Foster K., Lateef S., et al. The use of short-echo-time (1)H MRS for childhood cerebellar tumours prior to histopathological diagnosis. Pediatr Radiol 37 11 (2007) 1101-1109
114. Hattingen E., Raab P., Franz K., Zanella F.E., Lanfermann H., and Pilatus U. Myo-inositol: a marker of reactive astrogliosis in glial tumors?. NMR Biomed (2007 Jun 11) [Epub ahead of print]
115. Harting I., Hartmann M., Jost G., Sommer C., Ahmadi R., et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 342 3 (2003) 163-166 22
116. Al-Okaili R.N., Krejza J., Wang S., Woo J.H., and Melhem E.R. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 26 Suppl. 1 (2006) S173-S189
117. Hartmann M., Heiland S., Harting I., Tronnier V.M., Sommer C., et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338 2 (2003) 119-122 27
118. Al-Okaili R.N., Krejza J., Woo J.H., Wolf R.L., O'Rourke D.M., et al. Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. Radiology 243 2 (2007) 539-550
119. Floeth F.W., Pauleit D., Wittsack H.J., Langen K.J., Reifenberger G., et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 102 2 (2005) 318-327
120. Meder J.F., Henry-Feugeas M.C., Oppenheim C., Naggara O., and Frédy D. Dementia: role of imaging. J Radiol 84 11 Pt 2 (2003) 1819-1828
121. Lehéricy S., Delmaire C., Galanaud D., and Dormont D. Neuroimaging in dementia. Presse Med 36 10 Pt 2 (2007) 1453-1463
122. Minati L., Grisoli M., and Bruzzone M.G. MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. J Geriatr Psychiatry Neurol 20 1 (2007) 3-21
123. van Oostrom J.C., Sijens P.E., Roos R.A., and Leenders K.L. 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res 1168 (2007 Sep 7) 67-71
124. Rigotti D.J., Inglese M., and Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 28 10 (2007) 1843-1849
125. Martin W.R. MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 9 4 (2007) 196-203
126. Shinno H., Inagaki T., Miyaoka T., Okazaki S., Kawamukai T., et al. A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. J Neurol Sci 260 1-2 (2007) 132-138 15
127. Brusse E., Maat-Kievit J.A., and van Swieten J.C. Diagnosis and management of early- and late-onset cerebellar ataxia. Clin Genet 71 1 (2007) 12-24
128. Boesch S.M., Schocke M., Bürk K., Hollosi P., Fornai F., et al. Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6. J Magn Reson Imaging 13 4 (2001) 553-559
129. Boesch S.M., Wolf C., Seppi K., Felber S., Wenning G.K., and Schocke M. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 25 3 (2007) 564-569
130. Gazulla J. An update on neurochemistry and pharmacological therapy of the cerebellar ataxias. Rev Neurol 45 1 (2007) 31-41 1-15
131. Abou-Saleh M.T. Neuroimaging in psychiatry: An update. J Psychosom Res 61 3 (2006) 289-293
132. Abbott C., and Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 19 (2006) 135-139
133. Théberge J., Bartha R., Drost D.J., Menon R.S., Malla A., et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159 11 (2002) 1944-1946
134. Frye M.A., Thomas M.A., Yue K., Binesh N., Davanzo P., et al. Reduced concentrations of N-acetylaspartate (NAA) and the NAA-creatine ratio in the basal ganglia in bipolar disorder: a study using 3Tesla proton magnetic resonance spectroscopy. Psychiatry Res 154 3 (2007) 259-265 15
135. Moore C.M., Frazier J.A., Glod C.A., Breeze J.L., Dieterich M., et al. Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Am Acad Child Adolesc Psychiatry 46 4 (2007) 524-534
136. Shibuya-Tayoshi S., Tayoshi S., Sumitani S., Ueno S.I., Harada M., and Ohmori T. Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy. Neuropsychopharmacol Biol Psychiatry (2007 Aug 22) [Epub ahead of print]